Advanced search
Publication Cover
Future Virology Volume 7, 2012 - Issue 9
Submit an article Journal homepage
37
Views
0
CrossRef citations to date
0
Altmetric
Special Report

HIV-Associated Sensory Neuropathy: Still a Problem in the Post-Stavudine Era?

Catherine L Cherry1 Infectious Diseases Unit, The Alfred Hospital, Centre for Virology, Burnet Institute & Faculty of Medicine, Nursing & Health Sciences, Monash University, Australia.;2 Brain Function Research Group, School of Physiology, Faculty of Health Sciences, University of Witwatersrand, South AfricaCorrespondence[email protected]
View further author information
,
Peter R Kamerman2 Brain Function Research Group, School of Physiology, Faculty of Health Sciences, University of Witwatersrand, South AfricaView further author information
,
David LH Bennett3 Neurorestoration Group, CARD Wolfson, King‘s College London, UKView further author information
&
Andrew SC Rice4 Pain Research Group, Imperial College & Department of Pain Medicine & Department of Surgery & Cancer, Chelsea & Westminister Hospital, UKView further author information
Pages 849-854 | Published online: 21 Sep 2012

References

  • Keswani S , PardoC, CherryC, HokeA, McArthurJ. HIV-associated sensory neuropathies. AIDS16(16) , 2105–2117 (2002).
  • Kamerman P , WadleyA, CherryC. HIV-associated sensory neuropathy: risk factors and genetics. Curr. Pain Headache Rep.16(3) , 226–236 (2012).
  • Wadley A , CherryC, PriceP, KamermanP. HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans. J. Pain Symptom. Manage.41(4) , 700–706 (2010).
  • Smyth K , AffandiJ, McArthurJ et al. Prevalence and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. HIV Med. 8(6) , 367–373 (2007).
  • Maritz J , BenatarM, DaveJ et al. HIV neuropathy in South Africans: frequency, characteristics, and risk factors. Muscle Nerve 41(5) , 599–606 (2010).
  • Beadles W , JahnA, WeigelR, ClutterbuckD. Peripheral neuropathy in HIV-positive patients at an antiretroviral clinic in Lilongwe, Malawi. Trop. Doct.39(2) , 78–80 (2009).
  • Cherry C , AffandiJ, ImranD et al. Age and height predict neuropathy risk in HIV patients prescribed stavudine. Neurology73(4) , 315–320 (2009).
  • Meyer-Rosberg K , KvarnströmA, KinnmanE, GordhT, NordforsL, KristoffersonA. Peripheral neuropathic pain-a multidimensional burden for patients. Eur. J. Pain5(4) , 379–389 (2001).
  • Dworkin R , O‘connorA, AudetteJ et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin. Proc.85(Suppl. 3) , S3–S14 (2010).
  • Finnerup N , SindrupS, JensenT. The evidence for pharmacological treatment of neuropathic pain. Pain150(3) , 573–581 (2010).
  • Phillips T , CherryC, CoxS, MarshallS, RiceA. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One5(12) , e14433 (2010).
  • Clifford D , SimpsonD, BrownS et al. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J. Acquir. Immune Defic. Syndr.59(2) , 126–133 (2012).
  • Barohn R , GronsethG, LeforceB et al. Peripheral nervous system involvement in a large cohort of human immunodeficiency virus-infected individuals. Arch Neurol.50 , 167–170 (1993).
  • Woolley I , FaragherM, UgoniA, SpelmanD. An analysis of factors associated with HIV-related peripheral neuropathy. Neurol. Infect. Epidemiol.2 , 33–37 (1997).
  • Childs E , LylesR, SelnesO et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology52 , 607–613 (1999).
  • So Y , HoltzmanD, AbramsD, OlneyR. Peripheral neuropathy associated with acquired immunodeficiency syndrome - prevalence and clinical features from a population-based survey. Arch Neurol.45(9) , 945–948 (1988).
  • Ellis R , BadieeJ, VaidaF et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS25(14) , 1747–1751 (2011).
  • Thompson M , AbergJ, CahnP et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA304(3) , 321–333 (2010).
  • Ances B , VaidaF, RosarioD et al. Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS23(17) , 2317–2322 (2009).
  • Kumarasamy N , VenkateshK, CeceliaA et al. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDS22(4) , 227–244 (2008).
  • WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. WHO, Geneva, Switzerland (2009).
  • Hahn K , TrioloA, HauerP, McArthurJ, PolydefkisM. Impaired reinnervation in HIV infection following experimental denervation. Neurology68(16) , 1251–1256 (2007).
  • Mills E , BakandaC, BirungiJ et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann. Intern. Med.155(4) , 209–216 (2011).
  • Van Sighem A , GrasL, ReissP, BrinkmanK, De Wolf F. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS24(10) , 1527–1535 (2010).
  • Watters M , PoffP, ShiramizuB et al. Symptomatic distal sensory polyneuropathy in HIV after age 50. Neurology62(8) , 1376–1383 (2004).
  • Morgello S , EstanislaoL, SimpsonD et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy. The Manhattan HIV Brain Bank. Arch Neurol.61(4) , 546–551 (2004).
  • Affandi J , PriceP, ImranD, YuhaningsihE, DjauziS, CherryC. Can we predict neuropathy risk before stavudine prescription in a resource limited setting? AIDS Res. Hum. Retroviruses24(10) , 1281–1284 (2008).
  • Evans S , EllisR, ChenH et al. Peripheral neuropathy in HIV: prevalence and risk factors. AIDS25(7) , 919–928 (2011).
  • Nakamoto B , McMurtrayA, DavisJ et al. Incident neuropathy in HIV-infected patients on HAART. AIDS Res. Hum. Retroviruses26(7) , 759–765 (2010).
  • Lessells R , MutevedziP, CookeG, NewellM. Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural KwaZulu-Natal, South Africa. J. Acquir. Immune Defic. Syndr.56(3) , e79–e86 (2011).
  • Gallant J , DejesusE, ArribasJ et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med.354 , 251–260 (2006).
  • Gallant JE , StaszewskiS, PozniakAL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients. JAMA292(2) , 191–201 (2004).
  • Sax P , TierneyC, CollierA et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N. Engl. J. Med.361 , 2230–2240 (2009).
  • Sacktor N , NakasujjaN, SkolaskyR et al. Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology 72(2) , 165–170 (2009).
  • Forna F , LiechtyC, SolbergP et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J. Acquir. Immune Defic. Syndr.44(4) , 456–462 (2007).
  • Ellis R , RosarioD, CliffordD et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol. 67(5) , 552–558 (2010).
  • Cherry C , AffandiJ, BrewB et al. Hepatitis C seropositivity is not a risk factor for sensory neuropathy among HIV patients. Neurology 74(19) , 1538–1542 (2010).
  • WHO. UNAIDS World AIDS Day Report. WHO, Geneva, Switzerland (2011)
  • Cherry C , WesselinghS, LalL, McArthurJ. Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology65(11) , 1778–1781 (2005).
  • Ellis R , Marquie-BeckJ, DelaneyP et al. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann. Neurol. 64(5) , 566–572 (2008).
  • Pettersen J , JonesG, WorthingtonC et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann. Neurol. 59(5) , 816–824 (2006).
  • Cherry C , AffandiJ, RosenowA, McArthurJ, WesselinghS, PriceP. Cytokine genotype suggests a role for inflammation in nucleoside analog-associated sensory neuropathy (NRTI-SN) and predicts an individual‘s NRTI-SN risk. AIDS Res. Hum. Retroviruses24(2) , 117–123 (2008).
  • Chew C , CherryC, ImranD et al. Tumour necrosis factor haplotypes associated with sensory neuropathy in Asian and Caucasian human immunodeficiency virus patients. Tissue Antigens 77(2) , 126–130 (2010).
  • Banerjee S , MccutchanJ, AncesB et al. Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy. AIDS 25(2) , F1–F6 (2011).
  • Sacktor N , NakasujjaN, SkolaskyR et al. HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin. Infect. Dis. 49(5) , 780–786 (2009).
  • Zheng W , OuyangH, ZhengX et al. Glial TNFα in the spinal cord regulates neuropathic pain induced by HIV gp120 application in rats. Mol. Pain. 7 , 40 (2011).
  • Höke A , MorrisM, HaugheyN. GPI-1046 protects dorsal root ganglia from gp120-induced axonal injury by modulating store-operated calcium entry. J. Peripher. Nerv. Syst.14(1) , 27–35 (2009).
  • Wallace V , BlackbeardJ, SegerdahlA et al. Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain. Brain 130(10) , 2688–2702 (2007).
  • Wallace V , BlackbeardJ, PhebyT et al. Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy. Pain 133(1–3) , 47–63 (2007).
  • Attal N , BouhassiraD, BaronR et al. Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome? Eur. J. Pain 15(5) , 441–443 (2011).
  • Lauria G , HsiehS, JohanssonO et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur. J. Neurol. 17(7) , 903–912 (2010).
  • Maier C , BaronR, TölleT et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain 150(3) , 429–450 (2010).
  • Baron R , TölleT, GockelU, BroszM, FreynhagenR. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia. Differences in demographic data and sensory symptoms. Pain146(1–2) , 34–40 (2009).
  • Simpson D , SchifittoG, CliffordD et al. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology 74(5) , 413–420 (2010).
  • Laast V , ShimB, JohanekL et al. Macrophage-mediated dorsal root ganglion damage precedes altered nerve conduction in SIV-infected macaques. Am. J. Pathol. 179(5) , 2337–2345 (2011).
  • Kamerman P , MossP, WeberJ, WallaceV, RiceA, HuangW. Pathogenesis of HIV-associated sensory neuropathy: evidence from in vivo and in vitro experimental models. J. Peripher. Nerv. Syst.17(1) , 19–31 (2012).
  • Anderson T , DavidovichA, ArceoR, BrosnanC, ArezzoJ, SchaumburegH. Peripheral neuropathy induced by 2´,3´-dideoxycytidine. A rabbit model of 2´,3´-dideoxycytidine neurotoxicity. Lab. Invest.66(1) , 63–74 (1992).
  • Anderson T , DavidovichA, FeldmanD et al. Mitochondrial schwannopathy and peripheral myelinopathy in a rabbit model of dideoxycytidine neurotoxicity. Lab. Invest. 70(5) , 724–739 (1994).
  • Feldman D , BrosnanC, AndersonT. Ultrastructure of peripheral neuropathy induced in rabbits by 2´,3´-dideoxycytidine. Lab. Invest.66(1) , 75–85 (1992).
  • Wallace V , SegerdahlA, BlackbeardJ, PhebyT, RiceA. Anxiety-like behaviour is attenuated by gabapentin, morphine and diazepam in a rodent model of HIV anti-retroviral-associated neuropathic pain. Neurosci. Lett.448(1) , 153–156 (2008).
  • Maratou K , WallaceV, HasnieF et al. Comparison of dorsal root ganglion gene expression in rat models of traumatic and HIV-associated neuropathic pain. Eur. J. Pain 13(4) , 387–398 (2009).
  • Wallace V , SegerdahlA, LambertD et al. The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy. Br. J. Pharmacol. 151(7) , 1117–1128 (2007).
  • Power C , HuiE, VivithanapornP, AcharjeeS, PolyakM. Delineating HIV-associated neurocognitive disorders using transgenic models: the neuropathogenic actions of Vpr. J. Neuroimmune Pharmacol.7(2) , 319–331 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.